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Supplementary figure titles and legends 




(A) Heat plots for all identified metabolites in synchronized human U2OS cells. 
(B-E) Accumulation profiles of oscillating metabolites involved in branched-chain amino acid 
metabolism (B), GSH/GSSG metabolism (C), glycolysis (D), and TCA cycle (E), presented as 
mean ± SEM. Raw peak values for all metabolites were normalized to have a median of 1. 
(F) Relative total ATP levels from serum-shocked human skin fibroblasts measured at the 
indicated time points (JTK_Cycle, P=1.78*10
-15
). Right panel displays relative total ATP level at 
16 hours post-shock (peak of ATP content) and at 28 hours (trough of ATP content). 
(G) Cytosolic (cROS) and mitochondrial (mROS) reactive oxygen species levels were evaluated 
in serum-shocked human skin fibroblasts (JTK_Cycle, PmROS=5.40*10-21, PcROS=0.489). Right 
panel displays cROS and mROS levels at 16 hours post-shock (peak) and at 28 hours (trough)  
(H) Total NAD
+
 content assessed from brain of non-fasted wild-type mice kept in constant 
darkness every 4 hours for 24 hours (JTK_Cycle, P=1.23*10
-6
). Right panel displays relative 
total NAD
+
 level at CT4 (peak) and at CT16 (trough)). 
(I) Total NADH content from brain of non-fasted wild-type mice kept in constant darkness, 
assessed every 4 hours for 24 hours (JTK_Cycle, P=0.000168). Right panel displays relative 
total NAD
+
 level at CT4 (peak) and at CT16 (trough)  
All data are represented as mean ± SEM of at least three independent samples (n = 4 or 6 per 
time point) (F-I). **P<0.01, ***P < 0.001 for Student’s two-tailed t-test comparing time points 
(e.g. 16h versus 28h).  
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(A) Left panel, relative total ATP contents from serum-shocked human skin fibroblasts treated 
with cytosine β-D-arabinofuranoside (AraC, 100 μM) compared to non-treated cells (CTRL) 





). Right panel displays relative total ATP level at 16 hours post-shock (peak of 
ATP content) and at 28 hours (trough of ATP content) in control and treated conditions).  
(B) Percentage of BrdU- positive cells in absence and presence of AraC at 24 hours post-shock. 
All data are represented as mean ± SEM of at least three independent samples (n = 4 or 6 per 
time point) (A, B). **P<0.01, ***P < 0.001 for Student’s two-tailed t-test comparing single time 
points between CTRL and treated cells. 
(C) Circadian period length determined in dexamethasone - synchronized human skin fibroblasts 
transfected with Bmal1::luciferase reporter in presence of 2 deoxy-glucose (4.5 g/L) and AraC 
(100 μM) compared to control (CRTL). 
(D) Left panel shows relative total ATP levels measured in brain of wild-type mice kept in 
constant darkness (WT Brain) every 4 hours for 24 hours (7 time points, n=4 for each, 
JTK_Cycle, P=0.0077). Right panel displays relative total ATP level at circadian time 4 (CT4; 
peak of ATP content) and 16 (CT16; trough of ATP content) (). 
(E) Total NAD
+
 measured in serum-shocked human skin fibroblasts at the indicated time points 
(6 time points, n=6 for each, JTK_Cycle, P=2.18*10
-8
). Right panel displays relative total NAD
+
 
level at 16 hours post-shock (peak) and at 28 hours (trough)). 
(F) Total NADH measured in serum-shocked human skin fibroblasts at the indicated time points 
(6 time points, n=6 for each, JTK_Cycle, P=6.68*10
-5
). Right panel displays relative total NAD
+
 
level at 16 hours post-shock (peak) and at 28 hours (trough)). 
All data are represented as mean ± SEM (D-F). **P<0.01, ***P < 0.001 for Student’s two-tailed 
t-test comparing single time points (16 versus 28 hours). 
(G) OCR related to the proton leak (independent to ATP production) at 16 hours post-shock and 
28 hours post-shock in human skin fibroblast. 
(H) Extracellular Acidification Rate (ECAR) corresponding to glycolytic rate at 16 hours post-
shock and 28 hours post-shock in human skin fibroblast. 
All data are represented as mean ± SEM of three independent samples (n= 11 per time point). 
(I-P) Mitochondrial network morphology assessed at 4 hours intervals for 8 time points in 
synchronized fibroblasts (I, K, L, N, O) Intermediate network; (J, P) Tubular network; (M) 
Fragmented network. For each representative image, a zoom-in image is provided (400%). Scale 
bar = 25 μm.  
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(A-H) Mitochondrial network morphology assessed at 4 hours intervals for 8 time points in 
synchronized A172 glioma cells transfected with a GFP plasmid containing a mitochondrial 
targeting sequence. (A, C, G) Intermediate network; (B, H) Tubular network; (D, E, F) 
Fragmented network. For each representative image, a zoom-in image is provided (400%). Scale 
bar = 25 μm.  
(I) Mitochondrial network morphology assessed in liver sections from non-fasted wild-type mice 
kept in darkness condition at CT0 (i) and CT12 (ii). Scale bar = 50 μm. 
(J) Quantification of mitochondrial interconnectivity corresponding to the conditions A to H. On 
average 10`000-20`000 mitochondrial organelles were analyzed per time point (n = 25-30 
images per time point; JTK_Cycle, P = 0.000607). 
(K) Quantification of mitochondrial interconnectivity at CT0 and CT12 (n=6 sections per 
condition,). On average 2`500-8`500 mitochondrial units were analyzed per time point.  
Data are represented as average ± SEM (J, K). ***P<0.001 for Student’s two-tailed t test 
comparing single time points.  
8 
 




(A) Relative mRNA expression of complex I, IV and V subunits at 16 hours post-shock 
(corresponding to the peak in gene expression) and 28 hours post-shock (corresponding to the 










(B) Profile of relative mRNA expression of nuclearly-encoded genes related to mitochondrial 
fusion (MFN1, MFN2 and OPA1) and mitochondrial fission (DRP1 and hFIS1) in serum-
shocked human skin fibroblasts (JTK_Cycle, PMFN1=0.809, PMFN2=0.426, POPA1=0.175, 
PDRP1=0.215, PhFIS1=0.827). 
(C) Left panel, relative total ATP levels from serum-shocked human skin fibroblasts treated with 
Mdivi-1 (50 μM) compared to non-treated cells (CTRL) measured at the indicated time points 
(n=6 per time point, JTK_Cycle, PCTRL=5.36*10-20, PMdivi-1=0.8581). Right panel, relative total 
ATP level at 16 hours post-shock (peak of ATP content) and at 28 hours (trough of ATP content) 
in control and treated conditions. 
All data are represented as mean ± SEM of at least three independent samples (n=6 per time 
point,) (A- C). *P<0.05, **P<0.01, ***P<0.001 for Student’s two-tailed t test comparing single 
time points (A, B) or comparing single time points between CTRL and treated cells (C). 
(D) Relative mRNA expression of Bmal1 evaluated from in Drp1 
-/-
 MEFs compared to 
Drp1
lox/lox 
MEFs at 12, 18, 24, 30 and 36 hours post-shock (n=6 per time point, JTK_Cycle, P 
Drp1
lox/lox
 =0.000951, P Drp1
-/-
 =0.864).  
(E, F) Representative bioluminescence records determined in dexamethasone - synchronized 
human skin fibroblasts transfected with Bmal1::luciferase reporter in presence of (E) an AMPK 
inhibitor (compound C, 1 μM) and (F) a DRP1 inhibitor, P110 (1 μM), compared to control 
(CTRL) (n = 3).  
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Table S2: Primer sequences, related to STAR Methods section: “Quantitative real-time 
PCR”. 
 Primer Probe ID (Applied Biosystems) 
Fusion MFN1 Hs00250475_m1 
 MFN2 Hs00208382_m1 
 OPA1 Hs00323399_m1 
Fission DRP1 Hs00247147_m1 
 FIS1 Hs00211420_m1 
OXPHOS NDUFA2 (complex I) Hs00159575_m1 
 NDUFB5 (complex I) Hs00159582_m1 
 NDUFC1 (complex I) Hs00159587_m1 
 NDUFV2 (complex I) Hs00221478_m1 
 COX4I1 (complex IV) Hs00971639_m1 
 COX6A1 (complex IV) Hs01924685_g1 
 COX7A2 (complex IV) Hs01652418_m1 
 COX7B (complex IV) Hs00371307_m1 
 ATP5G2 (ATP synthase) Hs01096582_m1 
 ATP5C1 (ATP synthase) Hs01101219_g1 
 ATP5L (ATP synthase) Hs00758883_s1 
 
Primer Sequence (Microsynth) 
BMAL1 forward, 5'-GAAGACAACGAACCAGACAATGAG-3' 
reverse, 5'-ACATGAGAATGCAGTCGTCCAA-3' 
probe, 5'-Yakima Yellow-TGTAACCTCAGCTGCCTCGTCGCA-BHQ1-3' 
PER1 forward, 5'-CGCCTAACCCCGTATGTGA-3' 
reverse, 5'-CGCGTAGTGAAAATCCTCTTGTC-3' 
probe, 5'-Yakima Yellow-CGCATCCATTCGGGTTACGAAGCTC-BHQ1-3' 
PER2 forward, 5'-GGGCAGCCTTTCGACTATTCT-3' 
reverse, 5'-GCTGGTGTCCAACGTGATGTACT-3' 
5'-Yakima Yellow-CATTCGGTTTCGCGCCCGGG-BHQ1-3' 
 
